About: Mohammad Hojjat-Farsangi

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Mohammad Hojjat-Farsangi Goto Sponge NotDistinct Permalink

An Entity of Type : wikibase:Item, within Data Space : wikidata.demo.openlinksw.com associated with source document(s)

researcher

Attributes	Values
rdf:type	Item
description	forskare (sv) researcher (en) 연구원 (ko) গবেষক (bn) 研究者 (ja) investigador (es) дослідник (uk) वैज्ञानिक (hi) изилдөөчү (ky) 研究者 (zh) հետազոտող (hy) hulumtues (sq) onderzoeker (nl)
exact match	wds:Q38543823-1B33BD38-4AE5-4D8B-B069-93C7E4055F37
exact match	https://scigraph.springernature.com/person.0577522771.39
rdfs:label	Mohammad Hojjat-Farsangi (en) Mohammad Hojjat-Farsangi (es) Mohammad Hojjat-Farsangi (nl) Mohammad Hojjat-Farsangi (sl) Mohammad Hojjat-Farsangi (ast)
skos:prefLabel	Mohammad Hojjat-Farsangi (en) Mohammad Hojjat-Farsangi (es) Mohammad Hojjat-Farsangi (nl) Mohammad Hojjat-Farsangi (sl) Mohammad Hojjat-Farsangi (ast)
name	Mohammad Hojjat-Farsangi (en) Mohammad Hojjat-Farsangi (es) Mohammad Hojjat-Farsangi (nl) Mohammad Hojjat-Farsangi (sl) Mohammad Hojjat-Farsangi (ast)
Scopus author ID	wds:Q38543823-3C1FE94F-D1D4-4A89-8808-F2AB1A46EAB3 wds:Q38543823-8D73E248-EA11-4A87-A288-C304E916E5D6
Scopus author ID	24780380200 57195968594
instance of	wds:Q38543823-7879DA76-EDEA-4675-9625-D594CDCA636B
instance of	Homo sapiens
skos:altLabel	Farsangi MH (en) Mohammad Hojat Farsangi (en)
occupation	wds:Q38543823-F5D5B39C-5015-4AF7-A59A-C8E4C7EDE2BA
employer	wds:Q38543823-48931BB6-E68C-4A74-AA0B-D5F176567EF9 wds:Q38543823-CF76E0C9-50C7-4AAA-BD8B-BCF3E3FA37F6 wds:Q38543823-F5D76963-5D83-4AB7-B6A4-C2BAAC02B8D2
sex or gender	wds:Q38543823-32812B1E-5D50-4FF6-A4DA-7AF46B091468
occupation	researcher
employer	Karolinska Institutet Karolinska University Hospital Bushehr University of Medical Sciences
sex or gender	male
ORCID iD	wds:Q38543823-8FE7190A-F025-4F2C-8786-305DB35935D4
Dimensions author ID	wds:Q38543823-BB9B1F40-D493-4A0B-AC8C-7BC9D941F293
ORCID iD	https://orcid.org/0000-0002-0589-5523
ORCID iD	0000-0002-0589-5523
Dimensions author ID	0577522771.39
ResearcherID	wds:Q38543823-02750194-1112-4790-8BAA-FC6469D2403D
Publons author ID	wds:Q38543823-3389442F-C821-4FD8-BEB6-9EF04E95DA28
ResearcherID	E-8171-2018
Publons author ID	777423
Mendeley person ID	wds:Q38543823-A686D715-99FE-4911-9918-55AFEE9FE397
Mendeley person ID	mohammad-hojjat-farsangi
is about of	https://www.wikidata.org/wiki/Special:EntityData/Q38543823
is author of	Folate-conjugated nanoparticles as a potent therapeutic approach in targeted cancer therapy. Ligation of human Fc receptor like-2 by monoclonal antibodies down-regulates B-cell receptor-mediated signalling. Orphan receptor tyrosine kinases ROR1 and ROR2 in hematological malignancies Monoclonal antibodies against ROR1 induce apoptosis of chronic lymphocytic leukemia (CLL) cells. The skewed balance between Tregs and Th17 in chronic lymphocytic leukemia. Assessment of the immune system in 55 Iranian patients with vitiligo Cernunnos influences human immunoglobulin class switch recombination and may be associated with B cell lymphomagenesis Immunoglobulin heavy chain variable region gene usage and mutational status of the leukemic B cells in Iranian patients with chronic lymphocytic leukemia The receptor tyrosine kinase ROR1--an oncofetal antigen for targeted cancer therapy T cells from indolent CLL patients prevent apoptosis of leukemic B cells in vitro and have altered gene expression profile. Frequency analysis of HLA class I alleles in Iranian patients with progressive and non-progressive chronic lymphocytic leukemia The tyrosine kinase receptor ROR1 is constitutively phosphorylated in chronic lymphocytic leukemia (CLL) cells. Variation in WNT genes expression in different subtypes of chronic lymphocytic leukemia Increased frequency of CD8+ and CD4+ regulatory T cells in chronic lymphocytic leukemia: association with disease progression Small-molecule inhibitors of the receptor tyrosine kinases: promising tools for targeted cancer therapies Novel and emerging targeted-based cancer therapy agents and methods Induction of IgM, IgA and IgE antibodies in colorectal cancer patients vaccinated with a recombinant CEA protein The PI3K/AKT/mTOR pathway is involved in direct apoptosis of CLL cells induced by ROR1 monoclonal antibodies. Lack of Association Between rs17568 Polymorphism in OX40 Gene and Myocardial Infarction, Southern of Iran Fc receptor-like 1-5 molecules are similarly expressed in progressive and indolent clinical subtypes of B-cell chronic lymphocytic leukemia Mechanisms of tumor cell resistance to the current targeted-therapy agents. The imbalance of Th17/Treg axis involved in the pathogenesis of preeclampsia Dishevelled proteins are significantly upregulated in chronic lymphocytic leukaemia Nanoparticles and targeted drug delivery in cancer therapy Altered T-cell subpopulations in recurrent pregnancy loss patients with cellular immune abnormalities Adenosine and adenosine receptors in the immunopathogenesis and treatment of cancer. S1PR1 as a Novel Promising Therapeutic Target in Cancer Therapy The significant role of interleukin-6 and its signaling pathway in the immunopathogenesis and treatment of breast cancer CD73 as a potential opportunity for cancer immunotherapy Telomere length and expression of human telomerase reverse transcriptase splice variants in chronic lymphocytic leukemia Prostaglandin E2 as a potent therapeutic target for treatment of colon cancer Promising immunotherapy: Highlighting cytokine-induced killer cells ROR1 Is Expressed in Diffuse Large B-Cell Lymphoma (DLBCL) and a Small Molecule Inhibitor of ROR1 (KAN0441571C) Induced Apoptosis of Lymphoma Cells Smac mimetics as novel promising modulators of apoptosis in the treatment of breast cancer Targeting non-receptor tyrosine kinases using small molecule inhibitors: an overview of recent advances Immunophenotypic characterization of the leukemic B-cells from Iranian patients with chronic lymphocytic leukemia: association between CD38 expression and disease progression. Targeting Receptor Tyrosine Kinases Using Monoclonal Antibodies: The Most Specific Tools for Targeted-Based Cancer Therapy Sero-Epidemiological Study of Hepatitis E Virus among Thalassemia as High Risk Patients: A Cross-Sectional Survey in Jahrom, Southern, Iran Spontaneous Immunity Against the Receptor Tyrosine Kinase ROR1 in Patients with Chronic Lymphocytic Leukemia

Faceted Search & Find service v1.16.117 as of May 05 2024

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3239 as of May 5 2024, on Linux (x86_64-centos_6-linux-gnu), Single-Server Edition (378 GB total memory, 183 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software